Valeo Financial Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Valeo Financial Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-27,473	Closed	-$9.89K	–	693
2023 Q1	$9.89K	Hold	27,473	–	–	﹤0.01%	610
2022 Q4	$24.3K	Buy	27,473 +1,000	+4%	+$1.33K	﹤0.01%	527
2022 Q3	$42K	Buy	26,473 +7,000	+36%	+$15.9K	﹤0.01%	483
2022 Q2	$39K	Hold	19,473	–	–	﹤0.01%	477
2022 Q1	$45K	Buy	19,473 +5,000	+35%	+$15.6K	﹤0.01%	604
2021 Q4	$67K	Buy	14,473 +100	+0.7%	+$621	﹤0.01%	559
2021 Q3	$110K	Buy	14,373 +1,373	+11%	+$11.6K	0.01%	530
2021 Q2	$126K	Hold	13,000	–	–	0.01%	460
2021 Q1	$108K	Buy	13,000 +3,000	+30%	+$31.7K	0.01%	592
2020 Q4	$68K	Hold	10,000	–	–	﹤0.01%	682
2020 Q3	$112K	Buy	10,000 +6,000	+150%	+$54.9K	0.01%	455
2020 Q2	$25K	Buy	+4,000	New	+$15.3K	﹤0.01%	986

Other funds holding SRNE

SlateStone Wealth Jupiter, Florida $1.31B AUM 26.51% 1-Year Est. Return

KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

OAJ

Ogorek Anthony Joseph Williamsville, New York $403M AUM 22.57% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

TCOV

Trust Company of Vermont Brattleboro, Vermont $2.68B AUM

CFGS

Concourse Financial Group Securities Birmingham, Alabama $1.77B AUM 17.37% 1-Year Est. Return

Valeo Financial Advisors's SRNE Position: Q2 2023 in Review

Valeo Financial Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2023, closing a stake of 27,473 shares — an estimated $9.89K sold.

Valeo Financial Advisors first reported a position in SRNE in Q2 2020 and held it in 12 quarters. The position peaked at $126K in Q2 2021. 9 funds tracked by Wall St. Rank hold SRNE as of Q2 2023.

Valeo Financial Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
Valeo Financial Advisors sold 27,473 Sorrento Therapeutics, Inc. shares in Q2 2023, an estimated $9.89K.
Valeo Financial Advisors first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 12 quarters.
Valeo Financial Advisors's Sorrento Therapeutics, Inc. position peaked at $126K in Q2 2021.
9 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2023.

Based on Valeo Financial Advisors's 13F filing for Q2 2023, filed 14 Jul 2023.